Royal Philips (NYSE: PHG, AEX: PHI) announced the availability of triplets monitoring functionality for its industry-leading line of obstetrical care fetal and maternal monitors, Avalon FM20 antepartum and Avalon FM30 intrapartum. Philips is the first company to introduce a fetal monitor that enables non-invasive triplets monitoring with a single device.
Bayer HealthCare (BHC) and Topsun Science and Technology Co., Ltd. (Topsun, 600771.SS) together announced that BHC’s Consumer Care Division has signed an agreement in China to acquire the Western over-the-counter (OTC) cough and cold portfolio of Topsun Science and Technology Qidong Gaitianli Pharmaceutical Co., Ltd. for the consideration of RMB 1,072 million (approximately EUR 103 million) plus contingent payments of RMB 192 million (approximately EUR 19 million) subject to fulfilment of certain performance criteria.
In a first-of-its-kind study, UCLA researchers have shown that segments of the HIV-infected population who have little to no consistent outpatient medical care ? and yet are most in need of such services ? are overwhelmingly minorities, the poor and substance abusers.
Tackling wide variation could deliver benefits for patient care and better value for money. Improved NHS productivity and better efficiency could unlock resources worth ?2.2bn for the NHS and improve patient care at the same time, Health Minister Andy Burnham said today.
Royal Philips (NYSE: PHG, AEX: PHI) will showcase innovative cardiac solutions designed to streamline workflow and facilitate advanced information management at Cardiovascular Research Foundation?s (CRF) eighteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C.Shown for the first time ever in the U.S., the pre-release of the Philips Xcelera 2.1 Cardiovascular Information Solution is one of the key components to Philips integrated catheterization (cath) lab, which includes physiomonitoring, reporting and cardiovascular X-ray technologies to improve patient care and lab management.
Eli Lilly and Company has launched a major clinical trial evaluating ALIMTA (pemetrexed for injection) in extensive-stage small cell lung cancer (SCLC), a devastating and rapidly spreading form of lung cancer. This international trial, expected to be the largest ever to be conducted in SCLC(1), will assess the potential clinical benefit of pemetrexed in combination with carboplatin, a commonly-used chemotherapeutic agent, in direct comparison to the current leading treatment option of etoposide in combination with carboplatin.
TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced the initiation of a Phase IIb clinical trial for its lead product candidate, tezampanel, a novel pain compound in development for the treatment of acute migraine. An AMPA/kainate (AK) receptor antagonist, tezampanel offers a non-narcotic, non-vascular approach to the management of headache pain and represents a potentially promising alternative to current migraine treatments.
Case Western Reserve University’s Technology Transfer Office has entered a worldwide exclusive licensing agreement with TRACON Pharmaceuticals of San Diego, Calif., to develop Methoxyamine, a new cancer therapeutic that reverses cancer cell resistance to chemotherapy. Methoxyamine is a “first in class” drug that targets a specific DNA repair pathway.
A fast, sensitive and inexpensive diagnostic tool called MassTag PCR has been developed that can identify the specific pathogen that causes a particular case of respiratory infection, according to a new study funded by the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health (NIH). The research team ? headed by scientists in the Jerome L. and Dawn Greene Infectious Disease Laboratory at the Columbia University Mailman School of Public Health and their colleagues at the Wadsworth Center of the New York State Department of Health ? used MassTag PCR to identify previously undiagnosed pathogens that caused influenza-like illnesses in New York State during the winter of 2004.
Innocoll, Inc. announced that its wholly-owned subsidiary, Innocoll Pharmaceuticals, has received US 510k approval for CollaGUARD(TM), an advanced wound care product based on Innocoll’s proprietary CollaRx(TM) membrane technology. CollaGUARD is indicated for the management of superficial and deep wounds, including coverage of skin ulcers and temporary dermatoplasty in the case of lesion and burns. CollaGUARD has already received CE-mark approval for marketing in Europe.